Creatine kinase (CK), also known as creatine phosphokinase (CPK) or phosphocreatine kinase, is an enzyme (EC 126.96.36.199) expressed by various tissues and cell types. CK catalyses the conversion of creatine and utilizes adenosine triphosphate (ATP) to create phosphocreatine (PCr) and adenosine diphosphate (ADP). This CK enzyme reaction is reversible and thus ATP can be generated from PCr and ADP.
|PDB structures||RCSB PDB PDBe PDBsum|
|Gene Ontology||AmiGO / QuickGO|
In tissues and cells that consume ATP rapidly, especially skeletal muscle, but also brain, photoreceptor cells of the retina, hair cells of the inner ear, spermatozoa and smooth muscle, PCr serves as an energy reservoir for the rapid buffering and regeneration of ATP in situ, as well as for intracellular energy transport by the PCr shuttle or circuit. Thus creatine kinase is an important enzyme in such tissues.
Clinically, creatine kinase is assayed in blood tests as a marker of damage of CK-rich tissue such as in myocardial infarction (heart attack), rhabdomyolysis (severe muscle breakdown), muscular dystrophy, autoimmune myositides, and acute kidney injury.
In the cells, the "cytosolic" CK enzymes consist of two subunits, which can be either B (brain type) or M (muscle type). There are, therefore, three different isoenzymes: CK-MM, CK-BB and CK-MB. The genes for these subunits are located on different chromosomes: B on 14q32 and M on 19q13. In addition to those three cytosolic CK isoforms, there are two mitochondrial creatine kinase isoenzymes, the ubiquitous and sarcomeric form. The functional entity of the latter two mitochondrial CK isoforms is an octamer consisting of four dimers each.
While mitochondrial creatine kinase is directly involved in formation of phospho-creatine from mitochondrial ATP, cytosolic CK regenerates ATP from ADP, using PCr. This happens at intracellular sites where ATP is used in the cell, with CK acting as an in situ ATP regenerator.
|CKB||creatine kinase, brain, BB-CK|
|CKBE||creatine kinase, ectopic expression|
|CKM||creatine kinase, muscle, MM-CK|
|CKMT1A, CKMT1B||creatine kinase mitochondrial 1; ubiquitous mtCK; or umtCK|
|CKMT2||creatine kinase mitochondrial 2; sarcomeric mtCK; or smtCK|
Isoenzyme patterns differ in tissues. Skeletal muscle expresses CK-MM (98%) and low levels of CK-MB (1%). The myocardium (heart muscle), in contrast, expresses CK-MM at 70% and CK-MB at 25–30%. CK-BB is predominantly expressed in brain and smooth muscle, including vascular and uterine tissue.
Atomic structures of mitochondrial and cytosolic Creatine Kinase family membersEdit
A number of genuine CK structures have been solved by high-resolution electron microscopy and protein X-ray crystallography by the two research groups led by Dr. Theo Wallimann at the Biol. Dept. ETH Zurich and by Dr. Wolfgang Kabsch at MPI in Heidelberg. The first X-ray structure of a creatine kinase (CK) family member solved was that of sarcomeric muscle-type mitochondrial CK (s-mtCK (in 1996) (Fritz-Wolf et al. 1996 ), later followed by the structure of ubiquitous u-mtCK in 2000. (Eder et al. 2000 ). Both mitochondrial CK isoforms are building highly symmetrical octameric structures with 4-fold symmetry. (Schnyder et al. 1990 ; Schnyder et al. 1991 ). The atomic structure of cytosolic brain-type BB-CK was solved at 1.4 ! Angstoms in 1999. (Eder et al. 1999 ). Cytosolic BB-CK, as well as muscle-type MM-CK are both forming banana-shaped symmetric dimers, with one active site in each subunit. (Hornemann et al. 2000 ).
The mitochondrial creatine kinase (CKm) is present in the mitochondrial intermembrane space, where it regenerates phosphocreatine (PCr) from mitochondrially generated ATP and creatine (Cr) imported from the cytosol. Apart from the two mitochondrial CK isoenzyme forms, that is, ubiquitous mtCK (present in non-muscle tissues) and sarcomeric mtCK (present in sarcomeric muscle), there are three cytosolic CK isoforms present in the cytosol, depending on the tissue. Whereas MM-CK is expressed in sarcomeric muscle, that is, skeletal and cardiac muscle, MB-CK is expressed in cardiac muscle, and BB-CK is expressed in smooth muscle and in most non-muscle tissues. Mitochondrial mtCK and cytosolic CK are connected in a so-called PCr/Cr-shuttle or circuit. PCr generated by mtCK in mitochondria is shuttled to cytosolic CK that is coupled to ATP-dependent processes, e.g. ATPases, such as acto-myosin ATPase and calcium ATPase involved in muscle contraction, and sodium/potassium ATPase involved in sodium retention in the kidney. The bound cytosolic CK accepts the PCr shuttled through the cell and uses ADP to regenerate ATP, which can then be used as energy source by the ATPases (CK is associated intimately with the ATPases, forming a functionally coupled microcompartment). PCr is not only an energy buffer but also a cellular transport form of energy between subcellular sites of energy (ATP) production (mitochondria and glycolysis) and those of energy utilization (ATPases). Thus, CK enhances skeletal, cardiac, and smooth muscle contractility, and is involved in the generation of blood pressure.
CK is often determined routinely in a medical laboratory. It used to be determined specifically in patients with chest pain but this test has been replaced by troponin. Normal values at rest are usually between 60 and 174 IU/L, where one unit is enzyme activity, more specifically the amount of enzyme that will catalyze 1 μmol of substrate per minute under specified conditions (temperature, pH, substrate concentrations and activators.) This test is not specific for the type of CK that is elevated.
Creatine kinase in the blood may be high in health and disease. Exercise increases the outflow of creatine kinase to the blood stream for up to a week, and this is the most common cause of high CK in blood. Furthermore, high CK in the blood may be related to high intracellular CK such as in persons of African descent.
Finally, high CK in the blood may be an indication of damage to CK-rich tissue, such as in rhabdomyolysis, myocardial infarction, myositis and myocarditis. This means creatine kinase in blood may be elevated in a wide range of clinical conditions including the use of medication such as statins; endocrine disorders such as hypothyroidism; and skeletal muscle diseases and disorders including malignant hyperthermia, and neuroleptic malignant syndrome.
Furthermore, the isoenzyme determination has been used extensively as an indication for myocardial damage in heart attacks. Troponin measurement has largely replaced this in many hospitals, although some centers still rely on CK-MB.
- Bong SM, Moon JH, Nam KH, Lee KS, Chi YM, Hwang KY (November 2008). "Structural studies of human brain-type creatine kinase complexed with the ADP-Mg2+-NO3- -creatine transition-state analogue complex". FEBS Letters. 582 (28): 3959–65. doi:10.1016/j.febslet.2008.10.039. PMID 18977227.
- Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM (January 1992). "Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis". The Biochemical Journal. 281 ( Pt 1) (1): 21–40. doi:10.1042/bj2810021. PMC 1130636. PMID 1731757.
- Wallimann T, Hemmer W (1994). "Creatine kinase in non-muscle tissues and cells". Molecular and Cellular Biochemistry. 133-134 (1): 193–220. doi:10.1007/BF01267955. eISSN 1573-4919. PMID 7808454.
- Moghadam-Kia S, Oddis CV, Aggarwal R (January 2016). "Approach to asymptomatic creatine kinase elevation". Cleveland Clinic Journal of Medicine. 83 (1): 37–42. doi:10.3949/ccjm.83a.14120. PMC 4871266. PMID 26760521.
- Schlattner U, Tokarska-Schlattner M, Wallimann T (February 2006). "Mitochondrial creatine kinase in human health and disease". Biochimica et Biophysica Acta. 1762 (2): 164–80. doi:10.1016/j.bbadis.2005.09.004. PMID 16236486.
- Brewster LM, Mairuhu G, Bindraban NR, Koopmans RP, Clark JF, van Montfrans GA (November 2006). "Creatine kinase activity is associated with blood pressure" (pdf). Circulation. 114 (19): 2034–9. doi:10.1161/CIRCULATIONAHA.105.584490. PMID 17075013.
- Armstrong AW, Golan DE (2008). "Pharmacology of Hemostasis and Thrombosis". In Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Principles of pharmacology: the pathophysiologic basis of drug therapy. Philadelphia: Lippincott Williams & Wilkins. p. 388. ISBN 978-0-7817-8355-2. OCLC 76262148.
- Bishop ML, Fody EP, Schoeff LE, eds. (2004). Clinical chemistry: principles, procedures, correlations. Philadelphia: Lippincott Williams & Wilkins. p. 243. ISBN 978-0-7817-4611-3. OCLC 56446391.
- Johnsen SH, Lilleng H, Wilsgaard T, Bekkelund SI (January 2011). "Creatine kinase activity and blood pressure in a normal population: the Tromsø study". Journal of Hypertension. 29 (1): 36–42. doi:10.1097/HJH.0b013e32834068e0. PMID 21063205.
- Brewster LM, Coronel CM, Sluiter W, Clark JF, van Montfrans GA (2012-03-16). Saks V, ed. "Ethnic differences in tissue creatine kinase activity: an observational study". PLOS One. 7 (3): e32471. doi:10.1371/journal.pone.0032471. PMC 3306319. PMID 22438879.
- Hekimsoy Z, Oktem IK (2005). "Serum creatine kinase levels in overt and subclinical hypothyroidism". Endocrine Research. 31 (3): 171–5. doi:10.1080/07435800500371706. PMID 16392619.
- Johannsen S, Berberich C, Metterlein T, Roth C, Reiners K, Roewer N, Schuster F (May 2013). "Screening test for malignant hyperthermia in patients with persistent hyperCKemia: a pilot study". Muscle & Nerve. 47 (5): 677–81. doi:10.1002/mus.23633. PMID 23400941.
- O'Dwyer AM, Sheppard NP (May 1993). "The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome". Psychological Medicine. 23 (2): 323–6. doi:10.1017/s0033291700028415. PMID 8101383.